- 询价
- Biomedica Immunoassays
- BI-20472
- 2025年07月12日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
PRODUCT DETAILS
Assay characteristics:
| Cat.No.: | BI-20472 |
| Method: | Sandwich ELISA, HRP/TMB, 12x8-well strips |
| Sample type: | Serum, plasma (EDTA, citrate), protocols for cell culture supernatant and urine samples available |
| Standard range: | 0-320 pmol/l (7 serum based standards) |
| Standard points: | 0/10/20/40/80/160/320 pmol/l |
| Control: | 2 serum based controls |
| Sample size: | 20 µl / well |
| Incubation time: | 2 h / 1 h / 30 min |
| Unit conversion: | 1 pg/ml = 0.044 pmol/l (MW: 22.5 kDa) |
Sensitivity:
LOD: 1.9 pmol/l (0 pmol/l + 3 SD); LLOQ: 1.3 pmol/l
Precision:
Intra-assay (n=3) ≤ 1%, Inter-assay (n=7) ≤ 5%
Spike/Recovery:
The mean recovery of recombinant Sclerostin (spike: 26 pmol/l and 110 pmol/l) in human samples is:
serum (n=5): 93% / 86%
EDTA plasma (n=5): 94% / 93%
citrate plasma (n=1): 104% / 99%
Dilution linearity:
Expected average dilution of recombinant Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is:
serum (n=6): 98% / 86% / 89%
EDTA plasma (n=6): 102% / 99% / 91%
citrate plasma (n=1): 119% / 132% / 103%
Expected average dilution of endogenous Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is:
serum (n=7): 100% / 103% / 106%
EDTA plasma (n=6): 105% / 108% / 123%
citrate plasma (n=2): 91% / 91% / 103%
Cross reactivity:
The assay does not detect Noggin.
The assay does not detect Wise (SOSTDC1).
Serum values from apparently healthy individuals:
Median (serum, n=32): 61.5. pmol/l
Median (EDTA plasma, n=24): 87 pmol/l
Median (citrate plasma, n=24): 61.5. pmol/l
It is recommended to establish the normal range for each laboratory.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
